KRAS and neoplasm: As for the MMRD subtype, Robert C Grant et al. found that MMRD-PDACs presented higher tumour mutational burden, were less likely to have mutations in KRAS and SMAD4, were more likely to have basal-like transcriptional programmes yet had longer OS after surgery [33].